# Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress

> **NCT03642028** · PHASE4 · RECRUITING · sponsor: **VA Office of Research and Development** · enrollment: 190 (estimated)

## Conditions studied

- Sleep Initiation and Maintenance Disorders
- Stress Disorders, Posttraumatic

## Interventions

- **DRUG:** Suvorexant
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03642028
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-08-30
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03642028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03642028, "Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03642028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*